Samsung Bioepis sues again to invalidate Humira biosimilar
Healthcare 2022-06-30 2:57 pmBy Cindy Cameronne | Sydney
Please login to bookmark Close

Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi’s patent for a biosimilar of blockbuster arthritis drug Humira.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au